What does this research mean for the field?

An MRD-guided induction intensification strategy using daratumumab and carfilzomib prior to autologous stem cell transplantation is feasible and achieves high rates of MRD negativity in newly diagnosed multiple myeloma, though patients with high-risk disease remain prone to relapse. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the feasibility and outcomes of measurable residual disease (MRD)-guided induction intensification with daratumumab- and carfilzomib-based regimens prior to autologous stem cell transplantation in transplant-eligible newly diagnosed multiple myeloma.

September 8, 2026Leukemia & lymphoma/Leukemia and lymphoma

MRD-guided induction-intensification with daratumumab–carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

DYDaizo Yokoyama DMDaisuke Minakata SFShin-ichiro Fujiwara

Discussion

Member takes

Overview

Retrospective study demonstrates high response rates with MRD-guided daratumumab-carfilzomib intensification in multiple myeloma, indicating feasibility before autologous stem cell transplantation.

Key Points

To evaluate the feasibility and outcomes of measurable residual disease (MRD)-guided induction intensification with daratumumab- and carfilzomib-based regimens prior to autologous stem cell transplantation in transplant-eligible newly diagnosed multiple myeloma.
Retrospective single-institution study of 60 transplant-eligible patients undergoing autologous stem cell transplantation between 2020 and 2025.
Patients received initial induction (predominantly bortezomib, lenalidomide, and dexamethasone) and underwent treatment intensification, typically with daratumumab, carfilzomib, and dexamethasone, if persistent MRD was detected by multiparameter flow cytometry.
Pre-transplant MRD negativity was achieved in 67.3% (35/52) of evaluable patients, and post-transplant MRD negativity reached 93.8% (30/32).
At a median follow-up of 28.5 months, the 2-year progression-free survival was 87.3% and the 2-year overall survival was 98.0%.
R-ISS stage III, extramedullary disease, and high-risk cytogenetics were associated with poorer progression-free survival despite successful stem cell mobilization and engraftment.

Cite This Study

Yokoyama et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd74958e84d0ff5b45c90 https://doi.org/10.1080/10428194.2026.2723847

View Full Paper

Ask AI

Bookmark

September 8, 2026Leukemia & lymphoma/Leukemia and lymphoma

MRD-guided induction-intensification with daratumumab–carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

DYDaizo Yokoyama DMDaisuke Minakata SFShin-ichiro Fujiwara

Discussion

Member takes

Overview

Retrospective study demonstrates high response rates with MRD-guided daratumumab-carfilzomib intensification in multiple myeloma, indicating feasibility before autologous stem cell transplantation.

Key Points

To evaluate the feasibility and outcomes of measurable residual disease (MRD)-guided induction intensification with daratumumab- and carfilzomib-based regimens prior to autologous stem cell transplantation in transplant-eligible newly diagnosed multiple myeloma.
Retrospective single-institution study of 60 transplant-eligible patients undergoing autologous stem cell transplantation between 2020 and 2025.
Patients received initial induction (predominantly bortezomib, lenalidomide, and dexamethasone) and underwent treatment intensification, typically with daratumumab, carfilzomib, and dexamethasone, if persistent MRD was detected by multiparameter flow cytometry.
Pre-transplant MRD negativity was achieved in 67.3% (35/52) of evaluable patients, and post-transplant MRD negativity reached 93.8% (30/32).
At a median follow-up of 28.5 months, the 2-year progression-free survival was 87.3% and the 2-year overall survival was 98.0%.
R-ISS stage III, extramedullary disease, and high-risk cytogenetics were associated with poorer progression-free survival despite successful stem cell mobilization and engraftment.

Cite This Study

Yokoyama et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd74958e84d0ff5b45c90 https://doi.org/10.1080/10428194.2026.2723847

View Full Paper

Ask AI

Bookmark